C.R. Bard (NYSE:BCR) has notified buyers of its LifeStream covered iliac stent of a higher-than-anticipated restenosis rate among patients. The field notice issued by Bard, parent company BD and Irish catheter-maker ClearStream Technologies said the restenosis rate of 0.04% exceeds the acceptable failure rate of 0.01%. An unspecified number of restenosis complaints was reported following implantation of […]
Investors on Wall Street shrugged off the $51 million hit to C.R. Bard’s (NYSE:BCR) bottom line from a legal settlement, bumping shares up about 2% today.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
C.R. Bard (NYSE:BCR) is set to announce the purchase of Clearstream Technologies, an Ireland-based developer of catheters used in angioplasty procedures, according to a report by the U.K.-based Sky news service.
Murray Hill, N.J.-based Bard will pay a “price well in excess of today’s closing share price of 45.89p,” according to Sky.